Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Antengene Approved for Phase III Trial of SINE Candidate for Myeloma

publication date: Dec 11, 2020

Antengene, a Shanghai biopharma, is approved to start a China Phase III trial of ATG-010 (selinexor), an oral selective inhibitor of nuclear export (SINE). ATG010 will be administered in combination with bortezomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma. Two years ago, Antengene in-licensed the SINE candidate from Karyopharm of Boston in a four-drug deal worth up to $162 million. The drug is approved for use in the US to treat multiple myeloma and diffuse large B-cell lymphoma. More details....

Stock Symbol: (HK: 6996)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.